Breakthrough Therapy Designations

Enhertu, AstraZeneca, Breakthrough Therapy Designations, HER2-positive cancers, Daiichi Sankyo, antibody drug conjugate, Trastuzumab Deruxtecan

FDA grants breakthrough status to T-DXd for two HER2-positive cancers

Anika Sharma

Daiichi Sankyo and AstraZeneca have garnered FDA Breakthrough Therapy Designations (BTDs) for their Enhertu (T-DXd) therapy to treat two distinct ...